DeepMed Research

St. Jude Children's Research Hospital

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1962-01-01

Employees: -

Market Cap: -

Website: http://www.stjude.org/

Clinical Trials

Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

Phase 2

Terminated

Conditions: Sickle Cell Disease
Thalassemia

Interventions: Drug: Hydroxyurea Oral Capsule
Drug: Hydroxyurea

First Posted Date: 2019-01-31

Last Posted Date: 2022-03-18

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 1

Registration Number: NCT03825341

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: bendamustine
Drug: Etoposide
Drug: Doxorubicin
Drug: Bleomycin
Drug: Vincristine
Drug: Brentuximab Vedotin
Drug: Vinblastine
Drug: Cyclophosphamide
Drug: Prednisone
Drug: DTIC
Drug: Filgrastim
Other: Quality of Life Measurements
Radiation: Radiotherapy

First Posted Date: 2018-11-28

Last Posted Date: 2025-02-07

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 250

Registration Number: NCT03755804

Locations: 🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸
St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations

Antibiotic Resistance in Global Pediatric Oncology Centers

Completed

Conditions: Antibiotic Resistant Infection

First Posted Date: 2018-10-26

Last Posted Date: 2022-08-03

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 560

Registration Number: NCT03721562

Locations: 🇸🇻
Hospital Nacional de Niños Benjamín Bloom, San Salvador, El Salvador
🇬🇹
Unidad Nacional de Oncología Pediátrica, Guatemala, Guatemala
🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

and more 2 locations

Exploring Adherence Monitoring in Sickle Cell Disease

Active, not recruiting

Conditions: Sickle Cell Disease

First Posted Date: 2018-10-17

Last Posted Date: 2025-02-18

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 36

Registration Number: NCT03708731

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: GDC-0084
Radiation: radiation therapy

First Posted Date: 2018-10-04

Last Posted Date: 2023-01-18

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 27

Registration Number: NCT03696355

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

Phase 1

Active, not recruiting

Conditions: Severe Combined Immunodeficiency

Interventions: Drug: Anti-thymocyte globulin (rabbit)
Drug: Busulfan
Other: Donor Lymphocyte Infusion
Drug: Fludarabine
Drug: Thiotepa
Device: CliniMACS

First Posted Date: 2018-07-24

Last Posted Date: 2024-06-12

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 4

Registration Number: NCT03597594

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Postural Control Under Different Cognitive Loads in Adult Survivors of Acute Lymphoblastic Leukemia and Age-Matched Healthy Individuals

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2018-07-10

Last Posted Date: 2022-09-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 92

Registration Number: NCT03581045

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Phase 1

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia, in Relapse
Acute Lymphoblastic Leukemia, Refractory

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mesna
Device: CliniMACS
Biological: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)

First Posted Date: 2018-06-29

Last Posted Date: 2025-01-15

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 24

Registration Number: NCT03573700

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Evaluating the Clinical Utility of the T-SPOT.CMV Assay for the Prediction of CMV Reactivation Among Pediatric Patients Undergoing Hematopoietic Cell Transplant

Terminated

Conditions: CMV

Interventions: Diagnostic Test: T-SPOT®.CMV Test

First Posted Date: 2018-06-27

Last Posted Date: 2019-06-11

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 11

Registration Number: NCT03570411

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma

Early Phase 1

Recruiting

Conditions: Pheochromocytoma
Neuroblastoma

Interventions: Drug: 18F-DA

First Posted Date: 2018-05-30

Last Posted Date: 2025-02-13

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 20

Registration Number: NCT03541720

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy